Mechanistic and molecular insights into emerging anti-virulence therapeutics.

Antimicrobial resistance (AMR) poses a global health crisis and necessitates novel therapeutic strategies beyond traditional antibiotic, driving interest in anti-virulence (AV) strategies that disable pathogenicity rather than bacterial viability. This review provides an integrated overview of emerging AV approaches targeting quorum sensing, type III secretion systems, biofilm development, adhesion, toxin activity, iron acquisition, and host-pathogen interactions. We highlight representative phytochemicals, repurposed drugs, engineered inhibitors, nanomaterial-enabled formulations, and antibiotic-combination strategies that have shown promise across Gram-positive and Gram-negative pathogens. Across the literature, quorum sensing inhibitors and biofilm-disrupting agents are the most extensively explored, with many candidates demonstrating robust in vitro attenuation of virulence phenotypes. Type III secretion system inhibitors stand out for their mechanistic precision and, in several instances, stronger in vivo support, whereas host-directed and toxin-neutralizing strategies expand the therapeutic landscape but require cautious translational assessment. Importantly, the evidentiary strength of AV candidates is highly variable, ranging from docking-based hypotheses to animal-model validation, underscoring the need to distinguish preliminary leads from more advanced therapeutics. Collectively, the reviewed studies suggest that AV therapy is best positioned as a precision anti-infective strategy, particularly for chronic, device-associated, and multidrug-resistant infections where conventional antibiotics are less effective. Future progress will depend on improved mechanistic validation, rigorous safety and pharmacokinetic assessment, and translational frameworks that capture virulence suppression, host recovery, and treatment durability beyond bacterial killing alone.